Ocumension Therapeutics
5DG
Company Profile
Business description
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Contact
No. 1858 Yinzhongnan Road
Guoxiang Subdistrict
Wuzhong District
SuzhouJiangsu
CHNT: +86 2161493800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
489
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,777.90 | 50.80 | -0.58% |
CAC 40 | 7,877.66 | 110.95 | 1.43% |
DAX 40 | 24,562.44 | 355.53 | 1.47% |
Dow JONES (US) | 44,240.76 | 165.60 | -0.37% |
FTSE 100 | 8,860.32 | 6.14 | 0.07% |
HKSE | 23,892.32 | 255.75 | -1.06% |
NASDAQ | 20,418.46 | 5.95 | 0.03% |
Nikkei 225 | 39,821.28 | 132.47 | 0.33% |
NZX 50 Index | 12,768.61 | 90.41 | -0.70% |
S&P 500 | 6,225.52 | 0.00 | 0.00% |
S&P/ASX 200 | 8,538.60 | 52.10 | -0.61% |
SSE Composite Index | 3,493.05 | 4.43 | -0.13% |